CCNA2 and CDKN1A

Data Source:
BioGRID (affinity chromatography technology)
HPRD (in vivo, in vitro)

		CCNA2	CDKN1A
Description		cyclin A2	cyclin dependent kinase inhibitor 1A
Image
GO Annotations	Cellular Component	Cyclin-dependent Protein Kinase Holoenzyme Complex Female Pronucleus Male Pronucleus Nucleus Nucleoplasm Cytoplasm Cytosol Cyclin A2-CDK2 Complex	Cyclin-dependent Protein Kinase Holoenzyme Complex Nucleus Nucleoplasm Nucleolus Cytosol Nuclear Body Protein-containing Complex Perinuclear Region Of Cytoplasm PCNA-p21 Complex
	Molecular Function	Protein Binding Cyclin-dependent Protein Serine/threonine Kinase Regulator Activity Protein Kinase Binding Protein Domain Specific Binding	Protein Kinase Inhibitor Activity Cyclin-dependent Protein Serine/threonine Kinase Inhibitor Activity Protein Binding Protein Kinase Binding Cyclin-dependent Protein Kinase Activating Kinase Activity Cyclin Binding Ubiquitin Protein Ligase Binding Protein-containing Complex Binding Metal Ion Binding Protein Sequestering Activity
	Biological Process	Regulation Of Cyclin-dependent Protein Serine/threonine Kinase Activity G2/M Transition Of Mitotic Cell Cycle Regulation Of DNA Replication Ras Protein Signal Transduction Viral Process Histone Phosphorylation Protein Deubiquitination Animal Organ Regeneration Response To Glucagon Cellular Response To Platelet-derived Growth Factor Stimulus Cellular Response To Leptin Stimulus Mitotic Cell Cycle Phase Transition Cell Cycle G1/S Phase Transition Positive Regulation Of Transcription, DNA-templated Positive Regulation Of Fibroblast Proliferation Cell Division Cellular Response To Cocaine Cellular Response To Luteinizing Hormone Stimulus Cellular Response To Estradiol Stimulus Cellular Response To Hypoxia Cellular Response To Nitric Oxide Cochlea Development Cellular Response To Insulin-like Growth Factor Stimulus	Regulation Of Cyclin-dependent Protein Serine/threonine Kinase Activity G1/S Transition Of Mitotic Cell Cycle G2/M Transition Of Mitotic Cell Cycle Regulation Of Transcription By RNA Polymerase II Transcription Initiation From RNA Polymerase II Promoter Protein Import Into Nucleus Cellular Response To DNA Damage Stimulus DNA Damage Response, Signal Transduction By P53 Class Mediator Resulting In Cell Cycle Arrest DNA Damage Response, Signal Transduction By P53 Class Mediator Resulting In Transcription Of P21 Class Mediator Cell Cycle Arrest Mitotic G2 DNA Damage Checkpoint Ras Protein Signal Transduction Heart Development Negative Regulation Of Cell Population Proliferation Response To Toxic Substance Response To X-ray Response To Organonitrogen Compound Negative Regulation Of Gene Expression Cytokine-mediated Signaling Pathway Negative Regulation Of Cell Growth Positive Regulation Of B Cell Proliferation Animal Organ Regeneration Cellular Response To Extracellular Stimulus Negative Regulation Of Protein Binding Cellular Response To Amino Acid Starvation Cellular Response To Heat Wound Healing Tissue Regeneration Negative Regulation Of Phosphorylation Response To Drug Intrinsic Apoptotic Signaling Pathway In Response To DNA Damage By P53 Class Mediator Negative Regulation Of Apoptotic Process Positive Regulation Of Programmed Cell Death Negative Regulation Of Cyclin-dependent Protein Serine/threonine Kinase Activity Positive Regulation Of Protein Kinase Activity Response To Arsenic-containing Substance Positive Regulation Of Fibroblast Proliferation Protein Stabilization Response To Corticosterone Response To Hyperoxia Intestinal Epithelial Cell Maturation Cellular Response To Ionizing Radiation Cellular Response To Gamma Radiation Cellular Response To UV-B Mitotic Cell Cycle Arrest Cellular Senescence Replicative Senescence Stress-induced Premature Senescence Intrinsic Apoptotic Signaling Pathway Regulation Of Cell Cycle G1/S Phase Transition Negative Regulation Of Cyclin-dependent Protein Kinase Activity Positive Regulation Of Cyclin-dependent Protein Kinase Activity Negative Regulation Of Vascular Associated Smooth Muscle Cell Proliferation Negative Regulation Of Cardiac Muscle Tissue Regeneration Negative Regulation Of G1/S Transition Of Mitotic Cell Cycle Negative Regulation Of DNA Biosynthetic Process Positive Regulation Of Reactive Oxygen Species Metabolic Process
Pathways		Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 G0 and Early G1 Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes Telomere Extension By Telomerase Cdc20:Phospho-APC/C mediated degradation of Cyclin A Regulation of APC/C activators between G1/S and early anaphase SCF(Skp2)-mediated degradation of p27/p21 Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Ub-specific processing proteases Processing of DNA double-strand break ends TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation G2 Phase Orc1 removal from chromatin CDK-mediated phosphorylation and removal of Cdc6 Cyclin A/B1/B2 associated events during G2/M transition Cyclin A/B1/B2 associated events during G2/M transition p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry	SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint TFAP2 (AP-2) family regulates transcription of cell cycle factors Transcriptional regulation by RUNX2 RUNX3 regulates CDKN1A transcription Transcriptional regulation of granulopoiesis FOXO-mediated transcription of cell cycle genes Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins
Drugs		4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine 6-O-Cyclohexylmethyl Guanine [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE Variolin B	Arsenic trioxide
Diseases			Cervical cancer
GWAS		Mean corpuscular hemoglobin ( 32888494)	Atrial fibrillation ( 30061737 29892015) Colorectal cancer ( 22634755 30529582 31826910) Colorectal cancer or advanced adenoma ( 30510241) Coronary artery disease ( 29212778) Electrocardiogram morphology (amplitude at temporal datapoints) ( 32916098) Electrocardiographic conduction measures ( 23463857) Electrocardiographic traits ( 32602732 20062063) Glaucoma (primary open-angle) ( 29891935) Heart failure ( 31919418) Ischemic stroke ( 29531354) JT interval ( 29874175) Left ventricular fractional shortening ( 28394258) PR interval ( 32439900) Pulse pressure ( 30224653 30578418) QRS complex (Cornell) ( 27659466) QRS duration ( 30679814 27577874 31251759 25035420 31217584 21076409 27659466) Triglyceride levels ( 32203549) Triglycerides ( 27036123)
Interacting Genes		49 interacting genes: ARID4A BRCA1 BRCA2 BTG1 BUB1B CALM1 CDC20 CDC25C CDC6 CDK1 CDK2 CDK3 CDKN1A CDKN1B CDT1 DTNBP1 E2F1 E2F3 FANCC FEN1 H1-1 H1-5 HERC5 HIRA ITGB3BP KAT2B MAD2L1 MAGEA11 MYBL2 NFYA PGR POLA1 PRC1 PSMD4 PTMA RAD23A RB1 RBL1 RBL2 RPA1 SKP1 SKP2 SP1 TAF1 TP53 TRAF3IP1 UBE2C UBTF USP37	205 interacting genes: A1BG A2M ABL1 ACTB ACTL6B ADAMTS10 AKT1 AKT2 ALAS1 ANGPT2 APLP1 APP ATP5F1B ATP6V1A ATXN3 BAD BAG6 BCCIP CASP3 CCDC85B CCN3 CCNA1 CCNA2 CCNB1 CCNB2 CCND1 CCND2 CCND3 CCNE1 CCNE2 CCT7 CDC45 CDC5L CDC6 CDC7 CDK1 CDK14 CDK2 CDK3 CDK4 CDK6 CEBPA CELF3 CENPB CHEK2 CHGB CIZ1 CLEC3B COL4A5 COPS6 CPNE2 CPNE6 CSAD CSNK2A1 CSNK2B CTSB CZIB DAPK3 DCAF11 DDAH2 DEAF1 DOCK7 DTL DYNC1I1 EEF1A1 ESR1 EXT2 F13A1 FAF1 FBN3 FGB FHL3 FLAD1 FNDC11 GADD45A GADD45B GADD45G GAPDH GCKR GDF9 GET4 GMNN GNB2 GNB5 GOLGA2 H1-5 HADHB HDAC1 HDAC11 HDAC2 HDAC4 HDAC6 HERC5 HMGXB3 HNRNPK HOOK2 HOXD8 HPD IKBKG IKZF3 INCA1 ING5 INPP5K KIFC3 KLHL23 KMT2B KRT31 KRTAP3-1 LATS2 LRIF1 LRP2BP LRR1 LZTS2 MAP3K5 MAPK8 MCM10 MED31 MEOX2 MSH2 MTUS2 NFYA NGFR NKD2 NMRK2 NPRL2 NR1H2 NRBP1 OTUB1 PARP1 PCNA PDE4DIP PDHB PIM1 PKM POLD2 PRKACA PRKAR1B PRKN PSMA3 PSMC2 QARS1 RAB1A RACK1 RAI1 RB1 RBBP4 RBM48 REL RNF126 RNF144B RPL18 RPL35 RPS2 RRM2B S100A8 SDF4 SET SETDB1 SHISA6 SIPA1 SKP1 SKP2 SLC25A11 SP110 SPRED1 STAT3 STAT5B STUB1 SUMO3 TAF5L TCF4 TEX11 TFIP11 TK1 TLE1 TMSB4X TNIP1 TNIP2 TP53 TRAF1 TRIM3 TRIM54 TRMT2A TSG101 TTLL5 TUBA1A TUBB2B TUBB3 TXN TXNDC11 UBE2D1 UNC119 USHBP1 USP11 USP4 VIM VPS51 WDR73 WIZ XRCC6 YWHAQ ZBTB16 ZBTB48 ZNF135 ZNF431
Entrez ID		890	1026
HPRD ID		00453	00298
Ensembl ID		ENSG00000145386	ENSG00000124762
Uniprot IDs		P20248	A0A024RCX5 P38936
PDB IDs		1E9H 1FIN 1FVV 1GY3 1H1P 1H1Q 1H1R 1H1S 1H24 1H25 1H26 1H27 1H28 1JST 1JSU 1OGU 1OI9 1OIU 1OIY 1OKV 1OKW 1OL1 1OL2 1P5E 1PKD 1QMZ 1URC 1VYW 2BKZ 2BPM 2C4G 2C5N 2C5O 2C5V 2C5X 2C6T 2CCH 2CCI 2CJM 2I40 2IW6 2IW8 2IW9 2UUE 2UZB 2UZD 2UZE 2UZL 2V22 2WEV 2WFY 2WHB 2WIH 2WIP 2WMA 2WMB 2WPA 2WXV 2X1N 3EID 3EJ1 3EOC 3F5X 4BCK 4BCM 4BCN 4BCP 4CFM 4CFN 4CFU 4CFV 4CFW 4CFX 4EOI 4EOJ 4EOK 4EOL 4EOM 4EON 4EOO 4EOP 4EOQ 4EOR 4EOS 4FX3 5CYI 5IF1 5LMK 5NEV 6ATH 6GVA 6P3W 6Q6G 6Q6H 6RIJ	1AXC 2ZVV 2ZVW 4RJF 5E0U 6CBI 6CEJ 6CIV 6CIX 6P8H
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?